Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Joseph Redmond |
Contact Details
Address: 4902 Eisenhower Boulevard, Suite 125 Tampa, Florida 33634 United States | |
| Phone | 813 286 7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | OGEN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001174940 |
| CUSIP Number | 684023500 |
| ISIN Number | US6840235005 |
| Employer ID | 59-3410522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph Michael Redmond | President and Interim Principal Executive Officer |
| Janet Huffman | Chief Financial Officer, Secretary and Treasurer |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer and Member of Scientific Advisor |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 29, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 31, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 18, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 424B5 | Filing |